文摘
摘要目的:描述急性神经紊乱的频谱在住院患者中最近收到COVID-19 mRNA接种疫苗。
背景:COVID-19疫苗的前所未有的速度发展,使用新颖的信使rna技术和大规模疫苗接种程序产生的免疫接种后不良事件的担忧。
设计/方法:我们进行的多中心前瞻性研究7公共急性医院。住院病人被称为神经投诉,COVID-19 mRNA疫苗,BNT162b2和信使rna - 1273,在过去6周分为中枢神经系统(CNS)综合症、脑血管疾病,周围神经系统(pn)障碍、自主神经系统(ANS)障碍和免疫与压力相关的响应(ISRR)。了解我们的发现,数据来自国家免疫注册中心对个人和人口总数的接种疫苗在相应的时期。
结果:从2020年12月30日到2021年4月20日,1398074人(男性平均年龄59岁,54.5%)收到COVID-19 mRNA疫苗(86.7% BNT162b2, 13.3%信使rna - 1273);915344(65.5%)完成了2剂量。四百五十七例(0.03%)患者称为神经疾病(平均年龄67岁,男性61.5%;95.8%收到BNT162b2和4.2%信使rna - 1273);分为73(16.0%)中枢神经系统症状,286人(62.6%),脑血管疾病,59例(12.9%)pn障碍,ANS障碍和39 (8.5%)ISRRs。27有颅单神经病,11人有面神经麻痹。33个癫痫患者中,只有4是无缘无故的,发生在2周的疫苗接种。所有中风发生在个人与预先存在的心血管疾病的风险因素。我们记录2例脑静脉血栓形成;没有与血小板减少有关。 Five had mild flares of immune-mediated diseases.
结论:我们的观察性研究不建立因果关系描述疾病的疫苗和缺乏基线发病率数据是有限的几个条件。然而,我们没有看到任何明显的严重的神经系统的发病率与信使核糖核酸疫苗接种相关的信号。COVID-19接种疫苗的好处大于对神经系统不良事件的担忧。
披露:Koh博士没有披露。锄头博士没有披露。勇博士没有披露。卫生博士没有披露。吴作栋博士没有披露。勇博士没有披露。涂博士没有披露。制度的吊杆WS陈已收到个人薪酬在500 - 4999美元的范围为在科学咨询服务或数据安全监测委员会Livanova。制度的吊杆WS陈已经收到国家医学研究委员会的研究支持。吊杆WS陈已收到知识产权利益从发现或技术有关卫生保健。 Benjamin Yong Qiang Tan, 8130 has nothing to disclose. The institution of Dr. Yeo has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Astrazeneca. The institution of Dr. Yeo has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for stryker. Dr. Yeo has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for NUHS. Dr. Yeo has received stock or an ownership interest from cereflo. The institution of Dr. Yeo has received research support from NMRC. Amy May Lin Quek has nothing to disclose. Ms. Siow has nothing to disclose. Dr. Saini has nothing to disclose. Jasmyn De Leon has nothing to disclose. Dr. Rathakrishnan has nothing to disclose. Ms. Chen has nothing to disclose. Dr. Hui has nothing to disclose. Dr. Ahmad has nothing to disclose. Dr. Shwe has nothing to disclose. Dr. Tan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Tan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Viela Bio. Dr. Tan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Seet has nothing to disclose. Ms. Cai has nothing to disclose. Ms. Kuo has nothing to disclose. Dr. FOO has nothing to disclose. Umapathi Thirunagnam has nothing to disclose.
